Potential of resveratrol in the treatment of systemic lupus erythematosus (Review)

Mol Med Rep. 2024 Oct;30(4):182. doi: 10.3892/mmr.2024.13306. Epub 2024 Aug 19.

Abstract

Systemic lupus erythematosus (SLE) is a multi‑system chronic autoimmune disease with a complex occurrence and development process, associated with immune disorders, uncertain prognosis, and treatment modalities which vary by patient and disease activity. At present, the clinical treatment of SLE mainly focuses on hormones and immunosuppressants. In recent years, the research on new treatment strategies for SLE has been booming, and strong preclinical results and clinical research have promoted the development of numerous drugs (such as rituximab and orencia), but numerous of these drugs have failed to achieve effectiveness in clinical trials, and there are some adverse reactions. Recent evidence suggests that resveratrol (RSV) has the effect of ameliorating immune disorders by inhibiting overactivation of immune cells. In the present review, advances in research on the protective effects and potential mechanisms of RSV against SLE are summarized and the potential potency of RSV and its use as a promising therapeutic option for the treatment of SLE are highlighted.

Keywords: autoimmune disease; immune cell; resveratrol; systemic lupus erythematosus; treatment prospect.

Publication types

  • Review

MeSH terms

  • Animals
  • Humans
  • Lupus Erythematosus, Systemic* / drug therapy
  • Resveratrol* / pharmacology
  • Resveratrol* / therapeutic use

Substances

  • Resveratrol

Grants and funding

Funding: No funding was received.